株式会社ジーエヌアイグループ 2023年12月期 通期 決算説明資料

This document is the financial results presentation for GNI Group, covering the fiscal year ending December 2023. It includes an overview of the company, financial highlights, topics of interest, forecasts for the upcoming fiscal year, and additional information. The company reported a revenue of 26,010 million yen, a 49.3% increase from the previous year, and an operating profit of 13,108 million yen, reflecting an increase of 851.3%. The document emphasizes the company's global pharmaceutical research and development, manufacturing, and distribution, particularly its success in the Chinese market. GNI Group aims to continue focusing on new drug development and maintaining its growth trajectory.